SAN FRANCISCO, CA--(Marketwire - November 15, 2012) -
Medrio, a provider of advanced eClinical software as a service (SaaS) for clinical research, today announced key appointments to its board of directors. Richard H. Scheller, Executive Vice President of Research at Genentech, and Dave Lipscomb, founder and former executive at NetSuite, bring their deep expertise to Medrio.
"We are excited and fortunate to have Richard and Dave join our Board," said Mike Novotny, founder and CEO of Medrio. "With their global leadership and insights into innovation and technology, they are the perfect people to guide Medrio as we set new standards for our industry. We look forward to their counsel as Medrio continues its rapid growth and focus on providing the best possible experience for our customers."
Richard H. Scheller is a globally recognized leader in biomedical research and the Executive Vice President of Research and Early Development at Genentech. He is responsible for setting the strategy for Genentech's research and drug discovery activities, is a member of Genentech's Executive Committee, and is a member of the Roche Enlarged Corporate Executive Committee.
Prior to joining Genentech, Dr. Scheller served as professor of Molecular and Cellular Physiology at Stanford University and as an investigator with the Howard Hughes Medical Institute. He was appointed professor of Molecular and Cellular Physiology in 1993 and became an investigator with the Howard Hughes Medical Institute in 1994.
In addition to his work at Genentech, Dr. Scheller is an Adjunct Professor in the Department of Biochemistry and Biophysics, School of Medicine, University of California, San Francisco. Dr. Scheller has published over 200 papers in scientific journals, and his work in cell biology has earned him numerous awards, including the Alan T. Waterman Award from the National Science Foundation, the National Academy of Sciences Award in Molecular Biology, and the Kavli Prize in Neuroscience. Dr. Scheller is a member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences.
Dave Lipscomb brings great depth in software as a service (SaaS) to Medrio after spending 14 years at NetSuite since its inception in 1998. Holding the titles Senior Vice President of Engineering, Chief Information Officer, and Senior Vice President of Customer Loyalty, Mr. Lipscomb drove engineering, product management, and IT operations. Under his leadership, NetSuite enabled thousands of customers worldwide to manage their business in real-time, and the NetSuite service has achieved unprecedented uptime and reliability in the on-demand industry.
Prior to joining NetSuite, Mr. Lipscomb founded mBED Software and was a director in Oracle's New Media Division. Mr. Lipscomb has been building client/server and Web server software products for twenty years. He holds a B.S. in Computer Science from Stanford University.
For more information on Medrio's board please see www.medrio.com.
About Medrio Inc.
Medrio offers a unified eClinical software as a service (SaaS) suite with a fully hosted electronic data capture (EDC) system that drastically reduces study timelines and costs by putting study managers in control of their studies. Studies are built completely online without the need for any custom development and are ready in days instead of weeks in Medrio. Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by a number of leading contract research organizations (CROs), as well as biopharmaceutical and device companies. Founded in 2005, Medrio is headquartered in San Francisco. For more information visit www.medrio.com.